Beta Bionics secures FDA clearance for its first insulin patch pump, Mint, promising an earlier market launch and increasing competition in the industry dominated by Insulet.
Beta Bionics has won U.S. Food and Drug Administration clearance for Mint, its first insulin patch pump, a move that could sharpen competition in a market long led by Insulet. According to MedTech Dive, the device is designed for three-day wear and holds 200 units of insulin, using a mix of disposable and reusable parts.
The company expects to bring Mint to market in the first quarter of 2027, earlier than some previous expectations. Beta Bionics has said the pump will work with continuous glucose monitors from Abbott and Dexcom, giving patients more flexibility in how they build an automated insulin delivery system around the device.
The approval comes as Beta Bionics pushes further into algorithm-driven diabetes technology. The U.S. regulator has already cleared the company’s iLet ACE Pump and iLet Dosing Decision Software for people aged six and older with type 1 diabetes, forming the basis of its iLet Bionic Pancreas system. Beta Bionics has also submitted a separate dosing algorithm, 3D Intelligence, to the FDA for review.
Investors responded positively to the Mint decision, with Beta Bionics shares rising after the clearance, according to market reports. The approval gives the company a clearer route into the tubeless patch pump segment, where Insulet’s Omnipod line remains the best-known product, while Medtronic and other device makers continue to press for a larger share of the broader insulin delivery market.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
